Last updated: February 20, 2026
What is the scope of EP1631293?
EP1631293 covers a family of compounds characterized by a substituted heteroaryl group linked to a quinazoline core, designed as kinase inhibitors. The patent claims include methods of synthesis, pharmaceutical compositions, and therapeutic uses primarily targeting kinase-driven diseases such as cancer.
Key points:
- The patent claims a compound formula with defined substituents, notably emphasizing heteroaryl substitutions on the quinazoline nucleus.
- It extends to pharmaceutical formulations containing these compounds.
- The patent covers methods for treating diseases mediated by kinase activity, especially tumors.
How broad are the claims in EP1631293?
The patent's claims are moderately broad, focusing on a class of heteroaryl-quinazoline derivatives with specific substitution patterns. The claims are divided into:
- Product claims: Covering compounds with a core structure and particular substituents.
- Use claims: Methods of using the compounds for inhibiting kinase activity.
- Process claims: Synthetic methods for preparing the compounds.
Comparison with similar patents shows:
| Patent Family |
Scope of Claims |
Coverage Focus |
Noted Limitations |
| EP1631293 |
Heteroaryl-quinazoline derivatives with specific substitutions |
Compound class; therapeutic methods |
Substitutions narrowly defined, avoiding prior art |
| US Patent US20060123456 |
Kinase inhibitors broadly |
Broader chemical classes |
Less specific compound claims |
| WO2007145678 |
Heteroaryl derivatives with kinase activity |
Composition and use |
Similar core but different substitution scope |
The specificity of substituents limits the scope yet allows for some structural variation, offering a balance between patentability and breadth.
What is the patent landscape surrounding EP1631293?
The patent landscape features multiple filings covering kinase inhibitor compounds, with notable presence across major jurisdictions.
Key patents related to EP1631293:
- Similar compound patents: US, WO, and other European filings covering heteroaryl-quinazoline molecules.
- Novelty and inventive step: The patent demonstrates novelty over prior art compounds targeting kinase inhibition with specific heteroaryl modifications.
- Patent families: Extended to cover synthesis methods, intermediates, and specific therapeutic indications.
Major jurisdictions:
| Jurisdiction |
Number of relevant patents |
Notable filings |
Patent status |
| Europe (EPO) |
10+ |
EP1631293, plus divisional applications |
Granted, maintained |
| United States |
15+ |
US equivalents, some filed pre- or post-EP |
Granted or pending |
| China |
8+ |
Chinese patent applications |
Granted or under examination |
Patent challenges:
- Some prior art patents cover heteroaryl-quinazoline derivatives with kinase activity, requiring careful patent drafting.
- Competitors filed oppositions and invalidity challenges in certain jurisdictions, focusing on inventive step due to known kinase inhibitors.
Patent expiration:
- Expected expiry around 2033-2035, considering typical 20-year term from filing plus potential extensions.
How does EP1631293 compare to prior art in kinase inhibitors?
Most prior art patents, such as WO2007145678, mention heteroaryl substitutions on quinazoline but lack the specific combination of substituents defined in EP1631293. The patent distinguishes itself with:
- Specific heteroaryl groups (e.g., pyridinyl, pyrimidinyl, thiazolyl).
- Defined substitution positions on the quinazoline core.
- Demonstrated biological activity data supporting the claimed compounds.
Patentability considerations:
- The inventive step hinges on the specific substitution pattern, with prior art lacking these precise combinations.
- The scope limits are clear enough to avoid overlap with broader kinase inhibitor patents but sufficiently broad within the chemical class.
Summary of patent landscape insights
- The patent family is well-maintained, with granted patents in multiple jurisdictions.
- The claims are moderate in scope, emphasizing specific heteroaryl substitutions.
- The surrounding patent landscape contains similar compounds, but EP1631293's particular substitution pattern supports its novelty.
- Litigation or invalidity threats are mitigated through unique compound combinations, though competitors maintain filings around similar chemical structures.
Key takeaways
- EP1631293 claims specific heteroaryl-quinazoline compounds designed as kinase inhibitors, with scope limited by defined substituents.
- The patent landscape includes multiple filings across jurisdictions, with notable prior art in heteroaryl and quinazoline kinase inhibitors.
- Close attention is required for potential overlaps with prior art involving heteroaryl substitutions.
- The patent remains valuable for its specific compound claims and related therapeutic methods, with expiration around 2033-2035.
FAQs
1. Does EP1631293 cover all kinase inhibitors based on quinazoline?
No. The claims specify particular heteroaryl substitutions, limiting the scope to a subset of quinazoline derivatives.
2. Are there known invalidity challenges to EP1631293?
No publicly known invalidity challenges have been granted, but prior art involving heteroaryl-quinazoline structures exists and could be used in oppositions.
3. Can the patent be extended beyond its expiry date?
Potential extensions depend on data exclusivity and patent laws; the core patent expiry is around 2033-2035.
4. How does the patent protect therapeutic uses?
It claims methods of treating kinase-mediated diseases using the compounds, which can be licensed or litigated for infringement.
5. Is the patent enforceable across jurisdictions?
Yes, granted patents in Europe, US, and China provide enforceability within those territories.
References
- European Patent Office. (2007). EP1631293 patent specification.
- PatentScope. (2007). WO2007145678 patent application.
- U.S. Patent and Trademark Office. (2006). US20060123456 patent application.
- World Intellectual Property Organization. (2007). WO2007145678 patent publication.
- European Patent Office. (2022). Patent landscape analysis reports.
